Lymphomas, Leukemias and Hematologic Neoplasms
Contact Person:
Petra Neumann
Tel.: 0391-6713042
E-Mail:
Disease/Center |
Name of Study |
Short Description |
| ALL | GMALL- Register | Registry study for prospective imaging collection and data acquisition on diagnostic treatment as well as disease progression of ALL in adult patients. |
| ALL |
GMALL08/13 |
Randomized phase III study to assess safety and efficacy of GMALL 08/2013 protocol therapy in patients with newly diagnosed acute lymphoblastic leukemia. |
| AML | MicroIntest | Non-randomized observational study to assess the impact of the intestinal microbiome on disease progression, infections, and treatment outcome in hematologic oncology patients treated with cytostatic agents. |
| AML |
AMLSG 23-14 / Palbo-AL-1,2014-003647-34 |
Phase 1B/2A non-randomized study to evaluate safety and treatment response to palbociclib therapy in patients with newly diagnosed AML and an alteration in the MLL gene. |
| AML |
AMLSG 19-13 / |
Randomized multicenter phase 3 trial evaluating standard chemotherapy with or without crenolanib in patients with relapsed or refractory AML and FLT3 mutation. |
| AML | AMLSG 20-13 | Randomized phase 2 trial to evaluate the efficacy of intensive chemotherapy with or without volasertib in patients with newly diagnosed AML. |
| AML | AMLSG 30-18 | Randomized phase 3 study evaluating the efficacy of intensive chemotherapy versus intensive chemotherapy with CPX-351 in patients with newly diagnosed AML with intermediate or high-risk genetics. |
| AML |
ETAL-4 / HOVON-145 |
Randomized phase 3 trial to evaluate the efficacy of panobinostat maintenance therapy after allogeneic stem cell transplantation in patients with high-risk AML or MDS. |
| AML | AML003 / ARMADA 2000 | Randomized phase 3 study to evaluate the efficacy of HAM protocol versus HAM protocol with CPI-613 in the patients over 60 years of age with relapsed or refractory acute myeloid leukemia. |
| AML |
AMLSG 21-13 |
Randomized phase 3 trial evaluating intensive chemotherapy with or without dasatinib in patients with newly diagnosed AML with core binding factor (CBF-AML). |
| AML | AML Bio Register | Registry study of patient characteristics, biological disease profile, and clinical course in AML and high-risk MDS. |
| CLL | CLL-RT1 | Phase 2 nonrandomized study to evaluate the efficacy of the combination of zanubrutinib and tislelizumab in the patient with right transformation |
| Morbus Hodgkin |
HD2 |
Randomized phase 3 trial comparing first-line therapy between BEACOPP and BrECADD in patients with advanced Hodgkin's disease. |
| MPN | MPN- BioRegister | Registry study of biomaterial from BCR-ABL1 negative MPN diseases. |
| MPN - ET/PV |
RuxoBeat |
Randomized phase 3 trial evaluating the efficacy of ruxolitinib versus best possible therapy in patients with high-risk polycythaemia vera or high-risk essential thrombocytosis |
| MPN - PMF, SMF |
Pominc |
Phase 2 nonrandomized study to evaluate the efficacy of combining pomalidomide with ruxolitinib in patients with primary or secondary myelofibrosis |
| MPN - PMF, SMF | IMG-7289- CPT-102 | Phase 2 non-randomized study to assess MYC and IMG-7289 pharmacokinetics in patients with primary or secondary myelofibrosis. |
| MPN - PMF, SMF | Freedom 2 | Randomized phase 3 study to evaluate the efficacy and safety of fedratinib versus best possible therapy in patients with primary myelofibrosis or secondary myelofibrosis (after polycythaemia vera or after high-risk essential thrombocytosis according to DIPSS) and prior treatment with ruxolitinib. |
| Multiples Myelom |
DSMM XV |
Phase 2 nonrandomized trial comparing pomalidomide ixazomib and dexamethasone versus pomalidomide ixazomib dexamethasone and cyclophosphamide therapy in patients with relapsed or refractory multiple myeloma |
| Multiples Myelom |
DSMM XVII |
Randomized phase 3 trial comparing therapy with carfilzomib lenalidomide dexamethasone versus carfilzomib lenalidomide dexamethasone and elotuzumab in patients with newly diagnosed multiple myeloma before and after autologous stem cell transplantation with maintenance therapy with elotuzumab and lenalidomide versus lenalidomide monotherapy. |
| NHL | Alternative C |
Phase 2 non-randomized study to assess the efficacy of the combination of copanlisib and in patients with previously untreated follicular lymphoma and high tumor burden. |